Morbidity and mortality following major large bowel resection for colorectal cancer detected by a population-based screening program

2020 ◽  
pp. 096914132095736
Author(s):  
Lawrence F Paszat ◽  
Rinku Sutradhar ◽  
Elyse Corn ◽  
Jin Luo ◽  
Nancy N Baxter ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Large Bowel ◽  
Bowel Resection ◽  
Screening Program ◽  
Occult Blood ◽  
Population Based ◽  
Fecal Occult Blood ◽  
Operative Complications ◽  
Large Bowel Resection ◽  
Post Operative Complications

Background and aims In 2008, Ontario initiated a population-based colorectal screening program using guaiac fecal occult blood testing. This work was undertaken to fill a major gap in knowledge by estimating serious post-operative complications and mortality following major large bowel resection of colorectal cancer detected by a population-based screening program. Methods We identified persons with a first positive fecal occult blood result between 2008 and 2016, at the age of 50–74 years, who underwent a colonoscopy within 6 months, and proceeded to major large bowel resection for colon cancer within 6 months or rectosigmoid/rectal cancer within 12 months, and identified an unscreened cohort of resected cases diagnosed during the same years at the age of 50–74 years. We identified serious postoperative complications and readmissions ≤30 days following resection, and postoperative mortality ≤30 days, and between 31 and 90 days among the screen-detected and the unscreened cohorts. Results Serious post-operative complications or readmissions within 30 days were observed among 1476/4999 (29.5%) cases in the screen-detected cohort, and among 3060/8848 (34.6%) unscreened cases. Mortality within 30 days was 43/4999 (0.9%) among the screen-detected cohort, and 208/8848 (2.4%) among the unscreened cohort. Among 30 day survivors, mortality between 31 and 90 days was 28/4956 (0.6%) and 111/8640 (1.3%), respectively. Conclusion Serious post-operative complications, readmissions, and mortality may be more common following major large bowel resection for colorectal cancer between the ages of 50 and 74 among unscreened compared to screen-detected cases.

scholarly journals Morbidity and mortality after major large bowel resection of non-malignant polyp among participants in a population-based screening program

2020 ◽  
pp. 096914132096796
Author(s):  
Lawrence F Paszat ◽  
Rinku Sutradhar ◽  
Jin Luo ◽  
Nancy N Baxter ◽  
Jill Tinmouth ◽  
...  
Keyword(s):  
Large Bowel ◽  
Bowel Resection ◽  
Screening Program ◽  
Occult Blood ◽  
Population Based ◽  
Fecal Occult Blood ◽  
Malignant Polyp ◽  
Fecal Occult ◽  
Large Bowel Resection ◽  
Blood Screening

Background and aims Colonoscopy following positive fecal occult blood screening may detect non-malignant polyps deemed to require major large bowel resection. We aimed to estimate the major inpatient morbidity and mortality associated with major resection of non-malignant polyps detected at colonoscopy following positive guaiac fecal occult blood screening in Ontario's population-based colorectal screening program. Methods We identified those without a diagnosis of colorectal cancer in the Ontario Cancer Registry ≤24 months following the date of colonoscopy prompted by positive fecal occult blood screening between 2008 and 2017, who underwent a major large bowel resection ≤24 months after the colonoscopy, with a diagnosis code for non-malignant polyp, in the absence of a code for any other large bowel diagnosis. We extracted records of major inpatient complications and readmissions ≤30 days following resection. We computed mortality within 90 days following resection. Results For those undergoing colonoscopy ≤6 months following positive guaiac fecal occult blood screening, 420/127,872 (0.03%) underwent major large bowel resection for a non-malignant polyp. In 50/420 (11.9%), the resection included one or more rectosigmoid or rectal polyps, with or without a colonic polyp. There were one or more major inpatient complications or readmissions within 30 days in 117/420 (27.9%). Death occurred within 90 days in 6/420 (1.4%). Conclusions Serious inpatient complications and readmissions following major large bowel resection for non-malignant colorectal polyps are common, but mortality ≤90 days following resection is low. These outcomes should be considered as unintended adverse consequences of population-based colorectal screening programs.

SCREENING FOR COLORECTAL CANCER USING THE FECAL OCCULT BLOOD TEST: AN ACTUARIAL ASSESSMENT OF THE IMPACT OF A POPULATION-BASED SCREENING PROGRAM IN CANADA

2003 ◽  
Vol 19 (4) ◽  
pp. 715-723 ◽  
Author(s):  
Paul J. Villeneuve ◽  
Ann Coombs
Keyword(s):  
Colorectal Cancer ◽  
Screening Program ◽  
Occult Blood ◽  
Population Based ◽  
Fecal Occult Blood ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Fecal Occult ◽  
The Impact

Objectives:A series of randomized controlled trials have demonstrated that screening for colorectal cancer (CRC) using the fecal occult blood (FOB) test can decrease mortality from this disease. These findings were used to develop an actuarial model to estimate the impact that a FOB screening program for colorectal cancer would have on the Canadian population.Methods:The mortality experience of the year 2000 cohort of Canadians fifty to seventy-four years of age, with follow-up extending to 2010, was modelled according to three scenarios: no screening, annual screening, biennial screening. The primary screening tool was the FOB test using unrehydrated samples, with follow-up of positive test results using colonoscopy. The framework of the model was developed based on published findings from the relevant randomized controlled trials, available data, and a literature review that yielded parameter values for some model items.Results:During the 10-year follow-up of the cohort, we estimated that 4,444 and 2,827 deaths would be averted with annual and biennial FOB screening, respectively. We estimated that for an annual FOB screening program, approximately 3,400 FOB tests would be required to prevent one death, whereas 2,700 tests would be required within a biennial program.Conclusions:Our analysis documents the population health impact of using the FOB test to screen for CRC. Additional information on the natural history of the disease, and Canadian pilot data are needed to better model the effectiveness of population-based FOB screening programs.

Colorectal Cancer Screening by Fecal Occult Blood Testing: Results of a Population-Based Experience

2000 ◽  
Vol 86 (5) ◽  
pp. 384-388 ◽  
Author(s):  
Grazia Grazzini ◽  
Guido Castiglione ◽  
Antonio Isu ◽  
Paola Mantellini ◽  
Tiziana Rubeca ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Screening Test ◽  
Screening Program ◽  
Occult Blood ◽  
Fecal Occult Blood Testing ◽  
Population Based ◽  
Fecal Occult Blood ◽  
Blood Testing ◽  
Fecal Occult ◽  
Oncological Screening

Aims and background The study evaluated the results of an experimental screening protocol for colorectal cancer by fecal occult blood testing in a municipality of the Province of Florence. Methods A total of 15,235 subjects aged 50–70 years were invited to perform a 1-day immunochemical fecal occult blood testing without any dietary restrictions. All eligible subjects were sent a personal invitation letter, followed by a postal reminder to non-responders. Subjects with a negative stool test were advised to repeat screening after 2 years. Subjects with a positive screening test were invited to undergo full colonoscopy or a combination of left colonoscopy and a double contrast barium enema. Results A total of 6,418 subjects performed the screening test, with an overall compliance of 42.1%. A total of 268 compilers had positive test results. The positivity rate was 4.2%. Detection rate for cancer and for adenomas was 5.1‰ and 11.6‰, respectively. The positive predictive value was 14.3% for cancer and 32.5% for adenoma. A higher compliance was recorded in subjects born in the province of Florence or living in the centre of the town, in married subjects, and in women. The best results in compliance were associated with the direct distribution of fecal occult blood testing kits by general practitioners to their outpatients. Conclusions The study provides useful information about the efficiency and feasibility of a screening program for colorectal cancer using fecal occult blood testing. Compliance results confirm the importance of GP involvement in oncological screening.

scholarly journals Increasing Trend in the Incidence of Colorectal Cancer on Malaysia

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 216s-216s
Author(s):  
N. Ali ◽  
A. Ab Manan
Keyword(s):  
Colorectal Cancer ◽  
Cancer Registry ◽  
Health Informatics ◽  
Screening Program ◽  
Early Stage ◽  
Occult Blood ◽  
Population Based ◽  
Incidence Rates ◽  
Fecal Occult Blood ◽  
Fecal Occult

Background: Colorectal cancer (CRC) is the second most common cancer in Malaysia (13.2%). Aim: To study the epidemiologic trend of colorectal cancer in Malaysia and to suggest the strategy in reducing the incidence of CRC in Malaysia. Methods: Total of 13,693 cases of colorectal cancer diagnosed in 2007-2011 were extracted from the Malaysian National Cancer Registry (MNCR). MNCR is a population-based cancer registry which collects data from all government and private facilities (hospitals, clinics, laboratories, National Registration Department and Health Informatics, MOH) by passive notification and active case findings. The registry registers all new cancer cases among Malaysian citizen diagnosed in Malaysia into CanReg4 software. Data were explored using IARC tools and analyzed using CanReg4 software. Results: 55.8% of the colorectal cancer cases were in male and 44.2% in female. ASR was 14.6 per 100,000 population for male and 11.1 per 100,000 populations for female. The male to female ASR ratio was 1.3:1. The 5-years trend shows increasing incidence for both gender. The age-specific incidence rates of the cases were between 45 to 75 years old. The lifetime risk for males was 1 in 56 and in females was 1 in 74. Majority of the cancer were detected among Chinese followed by Malays and Indians. 66% of the colorectal cancer presented at advanced stage (stage 3 and 4) in males and 65% in female. Conclusion: The trend of colorectal cancer is increasing in Malaysia and most of the cancer cases were diagnosed at late stage. To increase the detection rate of CRC at early stage, Ministry of Health Malaysia has introduce screening program using immunochemical fecal occult blood test (iFOBT) since 2013. Tremendous campaigns also being carry out in the community to create awareness on the importance of colorectal cancer screening for early detection and treatment hence improved the survival.

scholarly journals Adverse events of colonoscopy in a colorectal cancer screening program with fecal immunochemical testing: a population-based observational study

2021 ◽  
Vol 09 (02) ◽  
pp. E224-E232
Author(s):  
Bernard Denis ◽  
Isabelle Gendre ◽  
Sarah Weber ◽  
Philippe Perrin
Keyword(s):  
Colorectal Cancer ◽  
Cancer Screening ◽  
Adverse Events ◽  
Colorectal Cancer Screening ◽  
Screening Program ◽  
Occult Blood ◽  
Population Based ◽  
Fecal Occult Blood ◽  
Fecal Occult ◽  
Cancer Screening Program

Abstract Background and study aims The aim of this study was to assess adverse events (AEs) associated with colonoscopy in the French colorectal cancer screening program with fecal occult blood test (FOBT). Patients and methods A retrospective cohort study was performed of all colonoscopies performed from 2015 to 2018 for a positive fecal immunochemical test (FIT) in patients aged 50 to 74 years within the screening program in progress in Alsace, part of the French program. AEs were recorded through prospective voluntary reporting by community gastroenterologists and retrospective postal surveys addressed to individuals screened. They were compared with those recorded in the previous program following colonoscopies performed from 2003 to 2014 for a positive guaiac-based FOBT (gFOBT). Results Of 9576 colonoscopies performed for a positive FIT, 6194 (64.7 %) were therapeutic. Overall, 180 AEs were recorded (18.8 ‰, 95 % CI 16.1–21.5), 114 of them (11.9 ‰, 95 % CI 9.7–14.1) requiring hospitalization, 55 (5.7‰, 95 % CI 4.2–7.3) hospitalization > 24 hours, and eight (0.8 ‰, 95 % CI 0.3–1.4) surgery. The main complications requiring hospitalization were perforation (n = 18, 1.9 ‰, 95 % CI 1.0–2.7) and bleeding (n = 31, 3.2 ‰, 95 % CI 2.1–4.4). Despite a significant increase in several risk factors for complication, the rate of AEs remained stable between gFOBT and FIT programs. Overall, we observed one death (1/27,000 colonoscopies) and three splenic injuries. Conclusions The harms of colonoscopy in a colorectal cancer screening program with FIT are more frequent than usually estimated. This study revealed six AEs requiring hospitalization > 24 hours (three bleeds, two perforations), one necessitating surgery, and 50 minor complications per 1000 colonoscopies.

scholarly journals The Colonoscopy Satisfaction and Safety Questionnaire (CSSQP) for Colorectal Cancer Screening: A Development and Validation Study

2019 ◽  
Vol 16 (3) ◽  
pp. 392 ◽  
Author(s):  
Alicia Brotons ◽  
Mercedes Guilabert ◽  
Francisco Lacueva ◽  
José Mira ◽  
Blanca Lumbreras ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Screening ◽  
Colorectal Cancer Screening ◽  
Screening Program ◽  
Occult Blood ◽  
Face Validity ◽  
Screening Colonoscopy ◽  
Fecal Occult Blood ◽  
Optimal Care ◽  
Screening Programs

Colonoscopy services working in colorectal cancer screening programs must perform periodic controls to improve the quality based on patients’ experiences. However, there are no validated instruments in this setting that include the two core dimensions for optimal care: satisfaction and safety. The aim of this study was to design and validate a specific questionnaire for patients undergoing screening colonoscopy after a positive fecal occult blood test, the Colonoscopy Satisfaction and Safety Questionnaire based on patients’ experience (CSSQP). The design included a review of available evidence and used focus groups to identify the relevant dimensions to produce the instrument (content validity). Face validity was analyzed involving 15 patients. Reliability and construct and empirical validity were calculated. Validation involved patients from the colorectal cancer screening program at two referral hospitals in Spain. The CSSQP version 1 consisted of 15 items. The principal components analysis of the satisfaction items isolated three factors with saturation of elements above 0.52 and with high internal consistency and split-half readability: Information, Care, and Service and Facilities features. The analysis of the safety items isolated two factors with element saturations above 0.58: Information Gaps and Safety Incidents. The CSSQP is a new valid and reliable tool for measuring patient’ experiences, including satisfaction and safety perception, after a colorectal cancer screening colonoscopy.

scholarly journals Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe

2021 ◽  
Vol 6 (1) ◽  
pp. 238146832098497
Author(s):  
Andrea Gini ◽  
Maaike Buskermolen ◽  
Carlo Senore ◽  
Ahti Anttila ◽  
Dominika Novak Mlakar ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Occult Blood ◽  
Population Based ◽  
Incidence Rates ◽  
Fecal Occult Blood ◽  
Evaluation Tool ◽  
Additional Tool ◽  
Crc Screening ◽  
Published Evidence ◽  
Microsimulation Models

Background. Validated microsimulation models have been shown to be useful tools in providing support for colorectal cancer (CRC) screening decisions. Aiming to assist European countries in reducing CRC mortality, we developed and validated three regional models for evaluating CRC screening in Europe. Methods. Microsimulation Screening Analysis–Colon (MISCAN-Colon) model versions for Italy, Slovenia, and Finland were quantified using data from different national institutions. These models were validated against the best available evidence for the effectiveness of screening from their region (when available): the Screening for COlon REctum (SCORE) trial and the Florentine fecal immunochemical test (FIT) screening study for Italy; the Norwegian Colorectal Cancer Prevention (NORCCAP) trial and the guaiac fecal occult blood test (gFOBT) Finnish population-based study for Finland. When published evidence was not available (Slovenia), the model was validated using cancer registry data. Results. Our three models reproduced age-specific CRC incidence rates and stage distributions in the prescreening period. Moreover, the Italian and Finnish models replicated CRC mortality reductions (reasonably) well against the best available evidence. CRC mortality reductions were predicted slightly larger than those observed (except for the Florentine FIT study), but consistently within the corresponding 95% confidence intervals. Conclusions. Our findings corroborate the MISCAN-Colon reliability in supporting decision making on CRC screening. Furthermore, our study provides the model structure for an additional tool (EU-TOPIA CRC evaluation tool: http://miscan.eu-topia.org ) that aims to help policymakers and researchers monitoring or improving CRC screening in Europe.

Sign in / Sign up

Export Citation Format

Share Document